Koh Tadokoro

Dr. Koh Tadokoro

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
KTKoh Tadokoro
Koh Tadokoro
YOYasuyuki Ohta
Yasuyuki Ohta
HIHaruhiko Inufusa
Haruhiko Inufusa
ALAlan Foo Nyuk Loon
Alan Foo Nyuk Loon
KAKoji Abe
Koji Abe
Oxidative stress plays a crucial role in Alzheimer’s disease (AD) from its prodromal stage of mild cognitive impairment. There is an interplay between oxidative stress and the amyloid β (Aβ) cascade via various mechanisms including mitochondrial dysfunction, lipid peroxidation, protein oxidation, glycoxidation, deoxyribonucleotide acid damage, altered antioxidant defense, impaired amyloid clearance, inflammation and chronic cerebral hypoperfusion. Based on findings that indicate that oxidative stress plays a major role in AD, oxidative stress has been considered as a therapeutic target of AD. In spite of favorable preclinical study outcomes, previous antioxidative components, including a single antioxidative supplement such as vitamin C, vitamin E or their mixtures, did not clearly show any therapeutic effect on cognitive decline in AD. However, novel antioxidative supplements can be beneficial for AD patients. In this review, we summarize the interplay between oxidative stress and the Aβ cascade, and introduce novel antioxidative supplements expected to prevent cognitive decline in AD.

1 November 2019 in Brain Research
Verified
Journal Article
Closed access
JSJingwei Shang
Jingwei Shang
TYToru Yamashita
Toru Yamashita
FTFeng Tian
Feng Tian
XLxianghong li
xianghong li
XLXia Liu
Xia Liu
KAKoji Abe
Koji Abe

24 August 2019 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
KTKoh Tadokoro
Koh Tadokoro
RMRyuta Morihara
Ryuta Morihara
YOYasuyuki Ohta
Yasuyuki Ohta
NHNozomi Hishikawa
Nozomi Hishikawa
SKSatoko Kawano
Satoko Kawano
KTKoh Tadokoro
Koh Tadokoro
Oxidative stress is part of the entire pathological process that underlies the development of Alzheimer’s disease (AD), including the mild cognitive impairment (MCI) stage. Twendee X (TwX) is a supplement containing a strong antioxidative mix of eight antioxidants, which has been shown to have a clinical and therapeutic benefit in AD model mice. Here, we conducted a multicenter, randomized, double-blind, and placebo-controlled prospective interventional study to evaluate the efficacy of TwX in mitigating MCI. The primary outcomes were differences in Mini-Mental State Examination (MMSE) and Hasegawa Dementia Scale-revised (HDS-R) scores between baseline and six months for placebo and TwX groups. Seventy-eight subjects with MCI were randomized into placebo ( n = 37) and TwX ( n = 41) groups. MMSE scores at six months differed significantly between the TwX and placebo groups ( p = 0.018), and HDS-R scores for the TwX group exhibited a significant improvement at six months relative to baseline ( p = 0.025). The TwX group did not show any change in affective or activities of daily living scores at six months. The present study indicates that strong antioxidative supplement TwX is clinical beneficial for cognitive function in subjects with MCI.

1 January 2023 in Cell Transplantation
Verified
Journal Article
Open access
TYToru Yamashita
Toru Yamashita
YNYumiko Nakano
Yumiko Nakano
RSRyo Sasaki
Ryo Sasaki
KTKoh Tadokoro
Koh Tadokoro
YOYoshio Omote
Yoshio Omote
KAKoji Abe
Koji Abe
Amyotrophic lateral sclerosis (ALS) is characterized by progressive loss of motor neurons. Multilineage-differentiating stress-enduring (Muse) cells are unique endogenous stem cells that show therapeutic effects on motor function in ALS mouse models. We conducted a single-center open phase II clinical trial to evaluate the safety and clinical effects of repeated intravenous injections of an allogenic Muse cell-based product, CL2020, in patients with ALS. Five patients with ALS received CL2020 intravenously once a month for a total of six doses. The primary endpoints were safety and tolerability, and the secondary endpoint was the rate of change in the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) score. In addition, serum tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), sphingosine-1-phosphate (S1P), cerebrospinal fluid chitotriosidase-1 (CHIT-1), and neurofilament light chain (NfL) levels were evaluated. The CL2020 treatment was highly tolerated without serious side effects. The ALSFRS-R score change trended upward at 12 months post-CL2020 treatment compared with that at 3 months pre-administration, but the difference was not statistically significant. Among five patients diagnosed with ALS, three exhibited a decrease in the rate of ALSFRS-R score change, one demonstrated an increase, and another showed no change. In addition, the patients’ serum IL-6 and TNF-α levels and cerebrospinal fluid CHIT-1 and NfL levels increased for up to 6 months post-treatment; however, their serum S1P levels continuously decreased over 12 months. These findings indicate a favorable safety profile of CL2020 therapy. In the near future, a double-blind study of a larger number of ALS patients should be conducted to confirm the efficacy of ALS treatment with CL2020.

1 April 2020 in Journal of Clinical Neuroscience
Verified
Journal Article
Closed access
KTKoh Tadokoro
Koh Tadokoro
YOYasuyuki Ohta
Yasuyuki Ohta
NHNozomi Hishikawa
Nozomi Hishikawa
ENEmi Nomura
Emi Nomura
YWYosuke Wakutani
Yosuke Wakutani
KTKoh Tadokoro
Koh Tadokoro

1 July 2020 in Brain Research
Verified
Journal Article
Closed access
NMNamiko Matsumoto
Namiko Matsumoto
TYToru Yamashita
Toru Yamashita
JSJingwei Shang
Jingwei Shang
TFTian Feng
Tian Feng
YOYosuke Osakada
Yosuke Osakada
KAKoji Abe
Koji Abe